US$ 23.07
contraindications for glp-1 agonists Table 5 from Glucagon-Like Peptide-1 (GLP-1) Receptor Drug Class Review Mapping the effectiveness and risks
Description
10.2337/dc14-1625 33 GoswamiC.IwasakiY.YadaT

Recent studies have shown that circulating DPP-4 plays a role in obesity and cardiovascular diseases, and may represent an important molecular link between obesity, diabetes, and cardiovascular disease (Rhrborn et al., 2015)

In summary, studies evaluating the associations between leptin and BMD in humans have shown mixed results [106]

GLP-1 agonists suppress appetite through peripheral gut hormone signaling and central satiety pathways

doi: 10.1152/ajpendo.1985.249.6.E603 177 HaunerHGlattingGKaminskaDPfeifferEF
